Skip to content
Participate in our active studiesSubscribe to our Mailing List
AB Science
Masitinib and AB8939 – Two compounds with breakthrough mechanism of action
AB ScienceAB Science
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in neurodegenerative disorders
    • Masitinib in inflammatory diseases
    • Masitinib in oncology
    • Masitinib in viral diseases
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Alzheimer’s Disease
      • Indolent Systemic Mastocytosis
      • Mast Cell Activation Syndrome
      • Severe Asthma
      • Prostate Cancer
      • Pancreatic Cancer
      • COVID-19
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webcasts
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
      • Board of Directors Charter
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
    • Events
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact
  • French
  • English
Search:
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in neurodegenerative disorders
    • Masitinib in inflammatory diseases
    • Masitinib in oncology
    • Masitinib in viral diseases
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Alzheimer’s Disease
      • Indolent Systemic Mastocytosis
      • Mast Cell Activation Syndrome
      • Severe Asthma
      • Prostate Cancer
      • Pancreatic Cancer
      • COVID-19
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webcasts
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
      • Board of Directors Charter
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
    • Events
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact

Category Archives: News

You are here:
  1. Home
  2. Category "News"

Live webcast on Thursday December 17, 2020 on masitinib’s results in Alzheimer’s Disease

2020By Alexis BERNARDDecember 16, 2020

16/12/2020 – AB Science will host a live webcast on December 17, 2020 on masitinib results in Alzheimer’s Disease

Positive Phase 2/3 study AB09004 with masitinib in Alzheimer’s Disease

2020By Alexis BERNARDDecember 16, 2020

16/12/2020 – AB Science announces that Phase 2B/3 study evaluating masitinib in Alzheimer’s disease met its primary endpoint

Live webcast on Friday December 11, 2020 on masitinib’s results in pancreatic cancer

2020By Alexis BERNARDDecember 8, 2020

08/12/2020 – AB Science will host a live webcast on December 11, 2020 with key opinion leaders to discuss recently reported results from the Phase 3 masitinib trial in pancreatic cancer

Positive confirmatory Phase 3 study AB12005 with masitinib in first line pancreatic cancer with pain

2020By Alexis BERNARDDecember 4, 2020

04/12/2020 – AB Science announces that confirmatory Phase 3 study AB12005 with masitinib in first line pancreatic cancer with pain met its primary objective to demonstrate increase in survival

Signature of a 15.0 million financing deal with the European Investment Bank

2020By Alexis BERNARDNovember 30, 2020

30/11/2020 – AB Science announces the signature of a 15.0 million financing deal with the European Investment Bank to support clinical development of masitinib in Covid-19

Equity financing for a maximum of 4 million shares with Alpha Blue Ocean’s PACT

2020By adminNovember 16, 2020

16/11/2020 – AB Science secures equity financing for a maximum of 4 million shares with Alpha Blue Ocean’s PACT

Financing of 4.5 million euros through the issuance of bonds convertible into new ordinary shares

2020By adminOctober 29, 2020

29/10/2020 – AB Science announces a financing of 4.5 million euros through the issuance of bonds convertible into new ordinary shares

Positive top-line Phase 3 results for oral masitinib in severe asthma

2020By adminOctober 20, 2020

20/10/2020 – AB Science announces positive top-line Phase 3 results for oral masitinib in severe asthma

Results from masitinib study AB07015 in severe asthma selected for presentation at an American Thoracic Society symposium

2020By adminOctober 13, 2020

13/10/2020 – Results from masitinib study AB07015 in severe asthma selected for presentation at an American Thoracic Society (ATS) symposium held on October 16, 2020

First half of 2020 results

2020By adminSeptember 30, 2020

30/09/2020 – AB Science reports its revenues for the first half of 2020

←1
23456789101112
…1314151617…
1819202122
23→
AB Science
© AB Science – All right reserved
Go to Top